Skip to content

Xenon Pharmaceuticals XENE Ratios & Valuation

FY'25FY'24FY'23FY'22
Profitability
Operating margin-4,974.3%-1,368.9%-940pp
Net margin-4,612.1%-1,328.9%-901pp
EBITDA margin-4,940.4%-1,354%-930pp
Free cash flow margin-3,732.2%-1,101.6%-713pp
Returns
Return on equity-51.8%-23.9pp-27.8%-5.7pp-22.1%-2.4pp-19.7%+2.1pp
Return on assets-48.3%-21.8pp-26.6%-5.4pp-21.2%-2.3pp-18.9%+1.8pp
Return on invested capital-73.7%-34.2pp-39.6%-10.4pp-29.2%-4.8pp-24.4%+6.4pp
Efficiency
Asset turnover0.0×0.0×
Liquidity
Current ratio13.4×-4.4×17.8×-5.8×23.6×-2.8×26.4×-12.6×
Quick ratio13.4×-4.4×17.8×-5.8×23.6×-2.8×26.4×-12.6×
Cash ratio4.8×+0.8×-1.4×5.5×+2.9×2.5×-9.7×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×
Debt-to-assets0.0×0.0×0.0×0.0×
Per Share
Book value per share$7.34-24.3%$9.69-30.1%$13.87+16.4%$11.92-5.5%
Valuation
Market capitalization$3.46B+15.9%$2.99B-7.3%$3.22B+30.7%$2.47B+53.0%
Enterprise value$3.27B+14.6%$2.85B-7.5%$3.08B+27.5%$2.42B+67.5%
Price / sales461.8×261.4×+174×
Price / book+2.0×+0.5×3.5×+0.1×3.4×+0.5×
EV / sales436.3×256.4×+178×
Free cash flow yield-8.1%-1.9pp-6.2%-1.3pp-4.9%-0.6pp-4.2%+0.2pp
Earnings yield-10%-2.1pp-7.8%-2.2pp-5.7%-0.6pp-5.1%-0.2pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Xenon Pharmaceuticals's ratios come from?
Every ratio is computed from Xenon Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.